(Q46220789)

20 December 2017

title

Fundamentals of cardiometabolic risk factor reduction: achieving and maintaining weight loss with pharmacotherapy or bariatric surgery (English)

1 reference

20 December 2017

0 references

0 references

Elisa Fabbrini

1

1 reference

20 December 2017

Samuel Klein

series ordinal

2

1 reference

20 December 2017

publication date

1 January 2008

1 reference

20 December 2017

published in

Clinical cornerstone

1 reference

20 December 2017

volume

9

1 reference

20 December 2017

issue

1

1 reference

20 December 2017

page(s)

41-8; discussion 49-51

1 reference

20 December 2017

Prevalence and Trends in Obesity Among US Adults, 1999-2000

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960027-7

7 January 2021

Increases in Clinically Severe Obesity in the United States, 1986-2000

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960027-7

7 January 2021

A review of long-term studies evaluating the efficacy of weight loss in ameliorating disorders associated with obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960027-7

7 January 2021

Obesity and disease management: effects of weight loss on comorbid conditions

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960027-7

7 January 2021

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960027-7

7 January 2021

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960027-7

7 January 2021

Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960027-7

7 January 2021

Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960027-7

7 January 2021

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960027-7

7 January 2021

Effect of sibutramine on weight maintenance after weight loss: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960027-7

7 January 2021

Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960027-7

7 January 2021

Long-term weight loss with sibutramine: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960027-7

7 January 2021

A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960027-7

7 January 2021

Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960027-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960027-7

7 January 2021

Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960027-7

7 January 2021

Sibutramine produces dose-related weight loss

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960027-7

7 January 2021

Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960027-7

7 January 2021

Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960027-7

7 January 2021

Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960027-7

7 January 2021

Meta-analysis: pharmacologic treatment of obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960027-7

7 January 2021

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960027-7

7 January 2021

Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960027-7

7 January 2021

The effect of managed care on medical education

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960027-7

7 January 2021

Co-administration of orlistat and cyclosporine in a heart transplant recipient

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960027-7

7 January 2021

Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960027-7

7 January 2021

Cannabinoid-1 Receptor Antagonist, Rimonabant, for Management of Obesity and Related Risks

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960027-7

7 January 2021

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960027-7

7 January 2021

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960027-7

7 January 2021

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960027-7

7 January 2021

Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960027-7

7 January 2021

Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960027-7

7 January 2021

NIH conference. Gastrointestinal surgery for severe obesity. Consensus Development Conference Panel

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960027-7

7 January 2021

Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960027-7

7 January 2021

Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960027-7

7 January 2021

Long-term mortality after gastric bypass surgery

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960027-7

7 January 2021

Solutions in weight control: lessons from gastric surgery

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960027-7

7 January 2021

Bariatric surgery: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960027-7

7 January 2021

Meta-analysis: surgical treatment of obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960027-7

7 January 2021

Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960027-7

7 January 2021

Impact of gastric bypass operation on survival: a population-based analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960027-7

7 January 2021

Bariatric surgery for morbid obesity: health implications for patients, health professionals, and third-party payers

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960027-7

7 January 2021

Laparoscopic adjustable gastric banding

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2808%2960027-7

7 January 2021

10.1016/S1098-3597(08)60027-7

Identifiers

DOI

1 reference

20 December 2017

1 reference

20 December 2017